Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419103 | 0.85 | KEAP1 (0.41) | HRH3MAPTSMN1; SMN2SIGMAR1 | |
| SCHEMBL6872234 | 0.83 | HRH3 (0.42) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL6872232 | 0.83 | HRH3 (0.42) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4526655 | 0.76 | KEAP1 (0.48) | HRH3CYP1A2MAPK1SMN1; SMN2SIGMAR1 | |
| SCHEMBL21202589 | 0.75 | HRH3 (0.44) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9412677 | 0.74 | — | — | |
| SCHEMBL11889487 | 0.72 | HRH3 (0.46) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL11833418 | 0.72 | HRH3 (0.37) | HRH3CARM1PRMT6PRMT8MEN1 | |
| SCHEMBL5238996 | 0.72 | SLC6A2 (0.39) | HRH3SMN1; SMN2 | |
| SCHEMBL22077060 | 0.71 | HRH3 (0.50) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008153701-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1692112-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1594849-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-07-04 | — | — | EP | claimed |
| US-20070149500-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | claimed |
| EP-1692112-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1686120-A2 | Methods and compositions utilizing quinazolinones | Cytokinetics, Inc. (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1594849-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050234037-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005061460-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2004064741-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
| US-8658656-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8470838-B2 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| US-6545004-B1 | Treating cellular proliferative diseases and disorders associated with KSP kinesin activity. | CYTOKINETICS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149500-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HRH3 4076/4885MAPT 2954/4885CYP1A2 4367/4885 |
| US-20050234037-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HRH3 4076/4885MAPT 2954/4885CYP1A2 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.